还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

' b- `3 A; |5 u" ]8 r: k+ S7 H                               
登录/注册后可看大图

* L9 L7 X9 v& g  A8 y2 c- P/ @% h" J  x请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  

3 m' }# t9 K, H: m3 \" Z
Sub-category:
  ]; E  M! I8 T. o8 nMolecular Targets
$ L2 u# B/ e+ @
# C5 e" C' A) b
/ U  G* z# P7 hCategory:
. o! |# u! }' v) B# LTumor Biology
/ h6 }; C9 D9 o
- {0 \' E. q0 [. {' e& K
Meeting:
2011 ASCO Annual Meeting
: }$ F" \) `$ e+ x4 G8 g: j# z% p

7 M9 }% J3 Y$ B6 U7 J( T2 \Session Type and Session Title:
Poster Discussion Session, Tumor Biology
* N$ P* B& R1 |  Y4 j2 M
( `; B7 P" c! Q/ ]
9 h0 v, M. U9 f3 NAbstract No:
, W7 X7 P$ `2 P$ i10517
, \! P: V" ^0 x& I/ l( s

( w  o% z! W$ T- M7 j% h; d: F4 JCitation:
' ^0 ?$ F$ K- \6 J* HJ Clin Oncol 29: 2011 (suppl; abstr 10517)

8 @- \# p* d* H: {2 B* F2 D
& W+ x: K6 G/ r8 |2 z; AAuthor(s):
6 l- j+ j" B7 C' J4 j/ ~J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

7 g% Q6 P% k( {
; j, W8 t: I) ^
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

) |7 c9 O- ~" ]7 J# A* ^Abstract Disclosures
( Q5 ?9 |; i0 Q
/ K/ ]2 N9 f# J  ]Abstract:

8 ?7 S; O, p  _
  Z6 Q4 L; k( |8 s8 @/ O3 fBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.


& {0 d( U1 m% A  }' J4 l) B9 N

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

0 s; e6 E# m* z6 j$ e3 p' _( y没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

5 K, E% ]) n' G5 j易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
% K4 j, O0 {) |; BALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

5 ^' d# L( {2 m2 c/ ]现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊